2020–2021 BCSC Basic and Clinical Science Course™
1 Update on General Medicine
Chapter 8: Hematologic Disorders
Highlights
-
Alternate-day dosing of iron may yield greater absorption with fewer gastrointestinal adverse effects than a daily regimen in patients with iron deficiency anemia.
-
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative in sickle cell disease and is strongly recommended for selected pediatric patients.
-
HCT may have a better than 90% cure rate for β-thalassemia when performed in a child with an HLA-identical sibling donor.
-
Edoxaban and betrixaban are 2 new factor Xa inhibitors recently approved for clinical use.
-
Idarucizumab is now available as an antidote for the thrombin inhibitor dabigatran; andexanet alfa has also been approved for reversal of rivaroxaban and apixaban.
-
Fostamatinib has recently received FDA approval for treatment of chronic idiopathic thrombocytopenic purpura (ITP).
Excerpted from BCSC 2020-2021 series: Section 1 - Update on General Medicine. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.